-
Something wrong with this record ?
Emerging Modes of Treatment of IgA Nephropathy
D. Maixnerova, V. Tesar
Language English Country Switzerland
Document type Journal Article, Review
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
33260613
DOI
10.3390/ijms21239064
Knihovny.cz E-resources
- MeSH
- Models, Biological MeSH
- Glomerulonephritis, IGA therapy MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Risk Factors MeSH
- Practice Guidelines as Topic MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
IgA nephropathy is the most common primary glomerulonephritis with potentially serious outcome leading to end stage renal disease in 30 to 50% of patients within 20 to 30 years. Renal biopsy, which might be associated with risks of complications (bleeding and others), still remains the only reliable diagnostic tool for IgA nephropathy. Therefore, the search for non-invasive diagnostic and prognostic markers for detection of subclinical types of IgA nephropathy, evaluation of disease activity, and assessment of treatment effectiveness, is of utmost importance. In this review, we summarize treatment options for patients with IgA nephropathy including the drugs currently under evaluation in randomized control trials. An early initiation of immunosupressive regimens in patients with IgA nephropathy at risk of progression should result in the slowing down of the progression of renal function to end stage renal disease.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21011834
- 003
- CZ-PrNML
- 005
- 20210507102806.0
- 007
- ta
- 008
- 210420s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms21239064 $2 doi
- 035 __
- $a (PubMed)33260613
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Maixnerova, Dita $u 1st Faculty of Medicine, General University Hospital, Department of Nephrology, Charles University, 128 08 Prague, Czech Republic
- 245 10
- $a Emerging Modes of Treatment of IgA Nephropathy / $c D. Maixnerova, V. Tesar
- 520 9_
- $a IgA nephropathy is the most common primary glomerulonephritis with potentially serious outcome leading to end stage renal disease in 30 to 50% of patients within 20 to 30 years. Renal biopsy, which might be associated with risks of complications (bleeding and others), still remains the only reliable diagnostic tool for IgA nephropathy. Therefore, the search for non-invasive diagnostic and prognostic markers for detection of subclinical types of IgA nephropathy, evaluation of disease activity, and assessment of treatment effectiveness, is of utmost importance. In this review, we summarize treatment options for patients with IgA nephropathy including the drugs currently under evaluation in randomized control trials. An early initiation of immunosupressive regimens in patients with IgA nephropathy at risk of progression should result in the slowing down of the progression of renal function to end stage renal disease.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a IgA nefropatie $x terapie $7 D005922
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a biologické modely $7 D008954
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Tesar, Vladimir $u 1st Faculty of Medicine, General University Hospital, Department of Nephrology, Charles University, 128 08 Prague, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 23 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33260613 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507102805 $b ABA008
- 999 __
- $a ok $b bmc $g 1650262 $s 1132213
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 21 $c 23 $e 20201128 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- LZP __
- $a Pubmed-20210420